Axovant Sciences Ltd. (AXON) Raised to “Hold” at BidaskClub
Axovant Sciences Ltd. (NASDAQ:AXON) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a report released on Wednesday.
Several other research analysts have also recently weighed in on the company. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Axovant Sciences in a report on Sunday, November 12th. Piper Jaffray Companies restated a “hold” rating on shares of Axovant Sciences in a report on Friday, November 10th. Zacks Investment Research cut Axovant Sciences from a “buy” rating to a “hold” rating in a report on Thursday, November 9th. Chardan Capital restated a “sell” rating and set a $3.00 target price on shares of Axovant Sciences in a report on Friday, November 3rd. Finally, Robert W. Baird restated a “hold” rating and set a $6.00 target price on shares of Axovant Sciences in a report on Wednesday, November 1st. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and six have issued a buy rating to the stock. Axovant Sciences currently has a consensus rating of “Hold” and a consensus price target of $14.13.
Shares of Axovant Sciences (AXON) traded up $0.19 during trading on Wednesday, hitting $5.65. The stock had a trading volume of 1,010,556 shares, compared to its average volume of 1,029,573. Axovant Sciences has a fifty-two week low of $4.60 and a fifty-two week high of $27.98. The company has a debt-to-equity ratio of 0.34, a quick ratio of 5.94 and a current ratio of 5.94.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in AXON. FMR LLC lifted its holdings in Axovant Sciences by 968.5% in the second quarter. FMR LLC now owns 7,235,632 shares of the biotechnology company’s stock valued at $167,794,000 after acquiring an additional 6,558,462 shares during the last quarter. Janus Henderson Group PLC acquired a new position in Axovant Sciences in the second quarter valued at approximately $47,854,000. OxFORD Asset Management LLP lifted its holdings in Axovant Sciences by 842.1% in the third quarter. OxFORD Asset Management LLP now owns 869,834 shares of the biotechnology company’s stock valued at $5,838,000 after acquiring an additional 777,505 shares during the last quarter. Capital Research Global Investors lifted its holdings in Axovant Sciences by 21.8% in the second quarter. Capital Research Global Investors now owns 3,453,800 shares of the biotechnology company’s stock valued at $80,094,000 after acquiring an additional 619,226 shares during the last quarter. Finally, Eagle Asset Management Inc. acquired a new position in Axovant Sciences in the third quarter valued at approximately $4,471,000. Hedge funds and other institutional investors own 99.69% of the company’s stock.
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.